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5 Viewpoint: How can data harmonisation benefit mental health research? An example of 
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12 Despite significant research on cannabis use, less is known about antecedents and effects of 
13 
14 less prevalent patterns of use, such as early daily or dependent use. Cohort studies typically 
15 
16 have insufficient samples (i.e., small cell sizes) and lack the statistical power to examine 
17 
18 
relationships between regular use and low prevalence adverse outcomes (e.g., suicide). 
20 
21 Consequently, individual cohort studies offer limited opportunity to explore the causes and 
22 
23 consequences of cannabis use patterns which confer the greatest burden of disease, namely, 
24 





30 One approach to addressing these limitations is to invest in new, large, prospective studies, 
31 
32 capable of providing the power needed to examine less frequent events. However, such 
33 
34 studies take decades to mature, are extremely costly and necessarily delay important health 
35 







43 One alternative is to make use of the available data by harmonising and pooling individual 
44 
45 participant data across individual cohorts. A multi-cohort consortium approach provides a 
46 
47 
number of potential advantages including: a) efficiency in the use of existing data, time and 
49 
50 resources; b) the capacity to bring together expert knowledge from across a range of 
51 
52 disciplinary boundaries; c) increased opportunity for knowledge translation and 
53 
54 dissemination; d) the increased generalisability afforded by combining data collected by 
55 














3 number of studies to answer questions that cannot be answered in individual cohorts. We 
4 





10 The Cannabis Cohorts Research Consortium (CCRC): An example of a multi-cohort 
11 
12 consortium approach 
13 
14 The bi-national Cannabis Cohorts Research Consortium (CCRC) is an example of a research 
15 
16 effort using integrated data analysis across multiple Australasian cohorts. The CCRC is a 
17 
18 
multi-organisational and multi-disciplinary international collaboration that brings together a 
20 
21 number of the most mature longitudinal studies of child and adolescent development across 
22 
23 Australia and New Zealand, including: the Australian Temperament Project (30 years/15 
24 
25 waves), the Christchurch Health and Development Study (37 years/23 waves), the Mater 
26 
27 
Hospital and University of Queensland Study of Pregnancy (33 years/8 waves), the 
28 
29 
30 Personality and Total Health Through Life Project (15 years/4 waves), the Victorian 
31 
32 Adolescent Health Cohort Study (20 years/10 waves), and the Western Australian Pregnancy 
33 





The CCRC was formed in 2006 and is co-ordinated by the National Drug and Alcohol 
40 
41 Research Centre (NDARC), at UNSW Australia. The CCRC stemmed from a recognised 
42 
43 need to better understand the link between cannabis use (particularly rarer patterns of high 
44 
45 use) and other substance use, mental health problems and psychosocial outcomes. The CCRC 
46 
47 
has first focussed on cannabis use across adolescence and young adulthood, in particular the 
49 
50 impact of regular patterns of use (i.e., daily and dependent use). Here, we describe an 
51 



















3 What cohorts are involved in the CCRC? 
4 
5 The Consortium brings together researchers from some of the largest and longest running 
6 
7 





12 1. The Australian Temperament Project (ATP) (Prior et al., 2000; Vassallo and Sanson, 
13 
14 2013) is a longitudinal study of social and emotional development that commenced in 
15 
16 1983 as a sample of 2443 infants (aged 4-8 months) and their parents. Maternal and 
17 
18 
Child Health nurses at Infant Welfare Centres, which successfully contacted 94% of 
20 
21 families with a new infant in the State of Victoria, Australia, assisted with enrolling 
22 
23 families for the study. Nurses distributed approximately 3000 questionnaires, and 
24 






30 Follow-up: The ATP has been studied on a total of 15 occasions: in childhood (4 
31 
32 months, 1, 2, 3, 5, 7, 9, 11, 12 years), adolescence (13, 15, 17, 19 years) and young 
33 
34 adulthood (24, 28 years). 
35 
36 2. The Christchurch Health and Development Study (CHDS) (Fergusson and Horwood, 
37 
38 
2001; Fergusson et al., 1989) is a longitudinal study of a birth cohort of 1265 
40 
41 children born in the Christchurch, New Zealand, urban region in 1977. These 
42 
43 children included 97% of all live births occurring during the recruitment period. 
44 
45 Follow-up: The cohort has now been studied on a total of 23 occasions (birth, 4 
46 
47 
months, yearly between 1-16 years, and then at 18, 21, 25, 30 and 35 years). 
49 
50 3. The Mater Hospital and University of Queensland Study of Pregnancy (MUSP) 
51 
52 Between 1981 and 1983, 8556 consecutive pregnant women attending for their first 
53 
54 clinic visit at average 18 weeks' gestation at the Mater Misericordiae Mothers' 
55 

















3 cohort (Keeping et al., 1989). Of those invited, 8458 (99%) agreed to participate in 
4 






Follow-up: The cohort has now been studied on eight occasions (18 weeks gestation, 
11 
12 birth, 4 years, 5 years, 14 years, 21 years, 27 years, 30 years). 
13 
14 4. The Personality and Total Health (PATH) Through Life Project (Anstey et al., 2012) 
15 
16 is a longitudinal cohort study that commenced in 1999 with the recruitment of 7485 
17 
18 
young (age 20–24 years at baseline, n=2404), midlife (age 40–44 years at baseline, 
20 
21 n=2530) and older (age 60–64 years at baseline, n=2551) adults randomly sampled 
22 
23 from the electoral roll of the Australian Capital Territory and the nearby city of 
24 
25 Queanbeyan, Australia. To align with the focus of the Consortium, only the youngest 
26 
27 
PATH cohort was included in the CCRC. The response rate amongst those contacted 
28 
29 




34 Follow-up: The cohort has been assessed on four occasions between 1999-2011 (age 
35 
36 20-24 years at baseline, 24-28 years, 28-32 years and 32-38 years). 
37 
38 
5. The Victorian Adolescent Health Cohort Study (VAHCS) (Patton et al., 2007) is a 
40 
41 longitudinal study of a representative sample of mid-secondary school adolescents in 
42 
43 Victoria, Australia. In 1992, participants were recruited via schools at the end of Year 
44 
45 9 (wave 1, mean age 14.9 years) or the start of Year 10 (wave 2, mean age 15.5 
46 
47 
years). Of the invited sample of 2032 students, 1943 (96%) were assessed at least 
49 
50 once during the first six waves. 
51 
52 Follow-up: Participants were assessed at six-monthly intervals on four further 
53 

















3 years); with a further four follow-ups in young adulthood: wave 7 (mean age 20.7 
4 
5 years) - wave 10 (mean age 35 years). 
6 
7 
6.   The Western  Australian Pregnancy Cohort (Raine) Study (Newnham et al., 1993; 
8 
9 
McNight et al., 2012) commenced in 1989. An estimated 3222 (Mountain, 2013) 
11 
12 pregnant women at around 18 weeks gestation from King Edward Memorial Hospital 
13 
14 in Perth, Western Australia, were invited to participate. Of these, 2900 pregnant 
15 





21 Follow-up: Information was collected from the mothers during pregnancy and 
22 
23 parent/guardian at each follow up until the participants were 17 years of age. 
24 
25 Participants were assessed at birth and at ages 1, 2, 3, 5, 8, 10, 14, 17, 20 and most 
26 
27 





32 How has the CCRC pooled data across cohorts? 
33 
34 There are two major approaches to data pooling. The first, commonly used method, combines 
35 
36 study level results meta-analytically. This approach is relatively straightforward to apply 
37 
38 
when there is a clear research hypothesis, the exposure and outcome variables are clearly and 
40 
41 consistently specified within and across studies, and the measure of effect size can be easily 
42 
43 interpreted (Curran and Hussong, 2009). However, because meta-analyses are based on 
44 
45 combining estimates at the study level, rather than at the individual participant level, 
46 
47 
investigation is limited by low sample size and power. That is, often the unit of analysis in 
49 



















3 The second approach to data pooling, pooling of participant-level data, is less commonly 
4 
5 used because gaining access to study participant data is more complicated (ethically and 
6 
7 
practically) than combining available study-level results. It is, however, ideally suited to 
8 
9 
investigations of low frequency exposures and/or outcomes such as rarer behaviours (e.g., 
11 
12 regular drug use) or genetic variants. The approach involves developing common scales of 
13 
14 measurement across cohorts (harmonisation) and pooling participant-level harmonised data 
15 
16 from multiple cohorts to create a single (large) integrated dataset of participants rather than 
17 
18 
studies. Data harmonisation and pooling allows models to be fitted directly to participant- 
20 
21 level data and, therefore, provides a number of advantages over study-level meta-analysis. 
22 
23 The major advantages of data harmonisation are that it (Curran and Hussong, 2009): 
24 
25 1. provides increased sample size which enables more powerful examination of less 
26 
27 
frequent exposures and outcomes; 
28 
29 
30 2. becomes feasible to explicitly model sources of between-study heterogeneity at 
31 
32 the level of the observed data; 
33 
34 3. improves the stability of model estimation and reduces the influence of outliers 
35 
36 and study specific characteristics; and, 
37 
38 






45 The CCRC has now developed a harmonised data set with over 20 variables, across four 
46 
47 
cohorts (ATP, CHDS, MUSP, VAHCS) with more than 7000 respondents, with the purpose 
49 
50 of further examining questions around frequent or dependent cannabis use that may not be 
51 
52 answered by analyses of individual cohorts. Selected PATH data on cannabis and depression 
53 
54 have also been harmonised within this data set (Horwood et al., 2012). We intend to 
55 
















3 support. Table 1 provides an overview of the key domains of interest for data harmonisation, 
4 
5 the availability of these data across the four main cohorts harmonised to date (ATP, CHDS, 
6 
7 












The annual attrition rate across the six cohorts was low; ranging from 0.5% to 3.9% per 
20 
21 annum among the cohorts; the retained (contactable) sample rates at most recent follow-up 
22 
23 range from 70% to 96%1. Although all studies showed evidence of some selection bias 
24 
25 attributable to sample attrition, analysis of the implications of such biases for study findings 
26 
27 
have shown these to be minimal (Silins et al., 2014). Table 2 provides descriptive data on 
28 
29 









What has it found? Key findings and publications 
40 
41 Findings from the analysis of the integrated data improved knowledge of the relationships 
42 
43 between cannabis use, mental health, other substance use and social development in young 
44 
45 people (Horwood et al., 2010; Horwood et al., 2012; Silins et al., 2014). For example, the age 
46 
47 
of initiation of cannabis use was found to be a significant factor in educational attainment, 
49 
50 with early use (i.e. < 15 years) accounting for up to 17% of the failure rate (population 
51 
52 attributable risk) in obtaining key educational milestones such as high school completion 
53 
54 compared with those who had not used by age 18 (Horwood et al., 2010). In relation to 
55 
56 















3 mental  health,  increasing frequency  of cannabis consumption was associated with increased 
4 
5 symptoms of depression, with the association strongest among adolescents (Horwood et al., 
6 
7 
2012). Evidence has also been found for the adverse sequelae of adolescent cannabis use 
8 
9 
across a broad range of young adult outcomes, including cannabis and other illicit drug 
11 
12 dependence and attempted suicide (Silins et al., 2014). Recently obtained additional NHMRC 
13 
14 funding for the existing CCRC datasets will enable extension of this harmonisation work to 
15 







23 What are the advantages and challenges? 
24 
25 Through the Consortium’s experience we have identified a range of advantages and 
26 
27 
challenges of the integrated data analysis and of the collaborative process by which the 
28 
29 
30 dataset was formed. Advantages of the CCRC analytic process include: access to high-quality 
31 
32 longitudinal studies that provide a rich pool of data across important developmental periods 
33 
34 from childhood, through adolescence and into adulthood; increased sample size and statistical 
35 
36 power to investigate rarer exposures and outcomes; the potential to compare model 
37 
38 
parameters to establish which effects are universal versus cohort specific; the efficient use of 
40 
41 existing resources; the development of infrastructure and expertise in Australia and New 
42 
43 Zealand in data harmonisation methodologies; the demonstrated feasibility of the approach 
44 







52 Advantages to the multi-cohort collaborative approach include: increased capacity to bring 
53 
54 together expert knowledge from across a range of disciplines; the establishment of positive 
55 














3 mentorship and training of younger researchers by senior academics, including co-authorship; 
4 
5 and the opportunity for significant knowledge dissemination and translation, with the 
6 
7 
potential to have greater impact than any one study alone. For example, media reporting of 
8 
9 
Silins et al. (2014) included 631 media citations in the month post-publication (including 
11 
12 online =373, radio =170, television=78, and print=10), across 29 countries (e.g., United 
13 
14 States, United Kingdom, Australia, New Zealand, Asia, Middle East, South America, Eastern 
15 





21 Challenges: One of the principal challenges for the CCRC is the cross study heterogeneity in 
22 
23 multi-cohort analyses. Common sources of between study heterogeneity include use of 
24 
25 different measures, sampling variation, timing of historical events and study design 
26 
27 
characteristics (Curran and Hussong, 2009). The CCRC cohorts do, however, have a number 
28 
29 
30 of advantages that reduce the effect of heterogeneity. Specifically, all cohorts: (1) are 
31 
32 population based samples; (2) were born about the same historical time and are culturally 
33 
34 similar; (3) adopted broadly similar data collection strategies (i.e., repeated measures 
35 
36 interview and questionnaire assessments); and, (4) have used broadly consistent measures of 
37 
38 




43 Harmonisation of data from these contemporary population studies across Australasia, with 
44 
45 due allowance for differences in study design and variability, augments our ability to 
46 
47 
generalise our findings to the region more realistically than is possible for any individual 
49 
50 study (Curran and Hussong, 2009). The prevalence of cannabis use in Australia and New 
51 
52 Zealand appears to be reasonably consistent with countries such as the United States, Canada, 
53 
54 and Western Europe (Copeland and Swift, 2009; Murray et al., 2007) and generalisation of 
55 






















There are also challenges related to developing and maintaining this collaborative work. 
11 
12 These include limited funding available in Australia and New Zealand for data 
13 
14 harmonisation; the large investment in time, resources and statistical expertise required to 
15 
16 harmonise data; limits to the number of cohorts that can be harmonised; the challenges of 
17 
18 
bringing people together and maintaining momentum, especially as the harmonisation 
20 
21 process can be slow; and the need for clear understanding and rules about ownership of ideas, 
22 
23 data and work product. There are also ethical constraints around data sharing (e.g., limitations 
24 










34 A data harmonisation approach to combining participant level data from large cohort studies 
35 
36 provides a unique opportunity to examine salient cannabis-related or other questions that are 
37 
38 
not possible to address in individual cohorts or using meta-analytic approaches. Although 
40 
41 acknowledging challenges to the combined cohort approach, the ongoing CCRC work has 
42 
43 demonstrated the capacity of the researchers to collaborate in data harmonisation and that 
44 
45 combining participant level data from several similar and large Australasian cohorts is 
46 
47 
feasible. Results from the CCRC study will allow cross-validation of important cannabis- 
49 
50 related research questions in Australasia and internationally. Recent funding through the 
51 
52 NHMRC will enable extension of the harmonisation work to alcohol, including the 
53 
54 antecedents and consequences of less prevalent patterns of youth alcohol use. The work of 
55 















3 substance use, mental health and social development in young people. Importantly, it enables 
4 
5 critical health related questions to be addressed which may not be adequately answered 
6 
7 





12 Can I get hold of the data? Where can I find out more? 
13 
14 Information about the CCRC can be obtained through the National Drug and Alcohol 
15 





21 enquires regarding the CCRC harmonised dataset are coordinated with Data Custodians by 
22 
23 Dr Delyse Hutchinson (d.hutchinson@unsw.edu.au) and Dr Edmund Silins 
24 
25 (e.silins@unsw.edu.au) at NDARC. In 2010 the Australian Research Alliance for Children 
26 
27 
and Youth (ARACY) recognised the collaborative work of the CCRC as a successful network 
28 
29 
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10 Problem use/abuse/dependence  1 2 1 
11 
12 Other Key Measures 
13 Depression/Suicide 
14 Symptoms/major depression 
15 Suicidal behaviours/self harm 
17 Other illicit drug use 
18 Frequency of use 
19 Problem use/abuse/dependence  
7  
20 Tobacco 
22 Age of onset    
23 Frequency of use    




27 Criminal offending 
28 Official contacts 
29 Income 
30 Financial income 
31 
32 Employment status 
33 Welfare dependence 
34 Conduct disorder/antisocial 
35 behaviour 
36 Note: ATP: Australian Temperament Project; CHDS: Christchurch Health and Development Study; MUSP: Mater Hospital 
37 and University of Queensland Study of Pregnancy; VAHCS: Victorian Adolescent Health Cohort Study. Check marks indicate 
38 data availability, footnotes indicate which published measures were used (if any). 
39 
1 
Composite International Diagnostic Interview (CIDI) (WHO, 1993) 
40 
2 
CIDI-Auto (WHO, 1997) 
41 
3 
Rutter Problem Behaviour Questionnaire (with depression items added) at age 11-12, 12-13 years (Rutter et al., 1970); 
42 Short Mood and Feelings Questionnaire at age 13-14, 15-16, 17-18 years (Angold et al., 1995); Depression Anxiety 
43 4 
44 
Stress Scales (DASS) at age 19-20, 23-24 years (Lovibond & Lovibond, 1995) 
Based on Diagnostic Interview Schedule for Children (DISC) (Costello et al., 1982) and Diagnosis and Statistical Manual 
(DSM-III-R) (APA, 1987) criteria at ages 15, 16 years; CIDI (WHO, 1993) thereafter 
45 5 CIDI-Auto (WHO, 1997) and Young Adult Self-Report (YASR) (Achenbach, 1997), used age 21 
46 6 Clinical Interview Schedule- Revised (CIS-R) (Lewis & Pelosi, 1990), used wave 1-7; CIDI-Auto (ICD-10) wave 9 
47 7 DSM used at each assessment; DSM-III-R (APA, 1997) used at 15, 16 years; CIDI/DSM-IV (APA, 1994) thereafter 
48 8 DSM-III-R (APA, 1987) at age 15 and 16 years; DSM-IV (APA, 1994) thereafter 
49 9 Self-report at ages 15-30 years; Self-reported Early Delinquency (SRED) (Moffitt & Silva, 1988) used ages 15 and 16 years; 
50 10 
Self-Report Delinquency Inventory SRDI (Elliott & Huizinga, 1989) used thereafter 
Assessed using 6 item scale adapted from Mak (1993) at age 21 years 
51 11 Adapted from Rutter Problem Behaviour Questionnaire at age 11-12, 12-13 years (Rutter et al., 1970); Antisocial 
52 behaviour adapted from Elliot & Ageton (1980), used age 19-20, 23-24 years 
53 12 Participant reports on the SRED (Moffitt & Silva, 1988) at age 15, 16 years were used to classify according to DSM-III-R 
54 (APA, 1987) symptom criteria for conduct disorder over the period 14-16 years 
55 13 Externalising behaviours assessed with YASR (Achenbach, 1997) at age 21 years 




















  - - 
   - 
   
   
 11  12  13  14 
 
 ATP CHDS MUSP VAHCS 
Measures of Cannabis Use 



















3 TABLE 2: Selected demographic and cannabis use characteristics of the CCRC harmonised cohort 




















































CHDS MUSP VAHCS 
Harmonised 
55 Note: ATP: Australian Temperament Project; CHDS: Christchurch Health and Development Study; MUSP: Mater Hospital and University of 
56 Queensland Study of Pregnancy; VAHCS: Victorian Adolescent Health Cohort Study.1Among: MUSP sample at age 21 years, ATP sample at 
age 24 years, VAHCS sample at age 24 years, CHDS sample at age 25 years. For information on the strategies used to harmonise variables 
57 across multiple cohorts see Horwood et al. (2010, 2012) and Silins et al. (2014). 2Reporting period: Past month in ATP, MUSP; past year in 
58 CHDS, VAHCS. 
3
Reporting period: Past 12 months in ATP, CHDS, VAHCS; past month in MUSP. 
Characteristic 
(%) 













(39.0) (48.7) (47.2) (45.8) (46.2) 
Female 
610
 515 1950 824 3899 
(61.0) (51.4) (52.3) (54.2) (53.8) 
Yes 
1129 444 2953 1276 5802 
(90.0) (42.2) (79.1) (84.1) (76.8) 
No 
122 609 779 242 1752 




 256 157 889 1742 
(44.3) (25.5) (4.2) (58.5) (23.9) 
No 
554 747 3603 631 5535 




 477 788 525 2122 
(34.2) (47.6) (21.2) (31.9) (28.9) 
Single 
640
 526 2938 1122 5226 




 827 2850 1401 5961 
(88.3) (82.5) (76.6) (86.3) (81.1) 
117 176 871 223 1387 
No 
(11.7) 
Age of cannabis use onset 
(17.6) (23.4) (13.7) (18.9) 
99 92 450 56 697 
<15 years 
(11.0)
 (9.2) (12.2) (3.68) (9.8) 
274 310 1029 411 2024 
15-17 years 
(30.3)
 (30.9) (28.0) (27.0) (28.5) 
530 600 2197 1053 4380 
Never before age 18 years 
(58.7)
 
Frequency of cannabis use2 
(59.9) (59.8) (69.3) (61.7) 
376 203 1878 366 2823 
Never 
(38.7) 
(21.2) (50.4) (27.2) (40.3) 
459 544 966 746 2715 
Less than monthly 
(47.2)
 (56.7) (25.9) (55.5) (38.8) 
79 76 419 45 619 
Monthly or more 
(8.1)
 (7.9) (11.3) (3.4) (8.8) 
39 81 257 94 471 
Weekly or more 
(4.0)
 (8.5) (6.9) (7.0) (6.7) 





(5.7) (5.5) (7.0) (5.3) 
43 38 288 102 471 
Yes 
(4.4) 
(3.8) (11.4) (6.7) (7.8) 
No 
927 965 2246 1415 5553 
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